Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

and a year earlier Gilead Sciences forged a $2.3 billion alliance with Nurix on degraders for oncology indications, with a $45 million upfront fee. BMS is extending its bid to cut costs by $1.5bn ...

Astellas has become the latest big pharma to pledge big bucks to a smaller company working on protein degraders ... as well as Gilead and Nurix. Gilead recently took its work with Nurix to ...

The efficacy of targeted protein degraders of intracellular proteins, such as proteolysis-targeting chimeras (PROTACs), has prompted efforts to develop similar approaches to target plasma membrane ...

At close: January 17 at 4:00:01 p.m. EST ...